Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus

Clinical Laboratory

Volumn 58, Issue 11-12, 2012, Pages 1231-1239

  De Vries, Rindert ^a   Dikkeschei, Bert D ^b   Sluiter, Wim J ^a   Dallinga Thie, Geesje M ^c   Van Tol, Arie ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

CETP; Cholesterol esterification; Cholesteryl ester transfer; Fibrate; LCAT; Statin; Type 2 diabetes mellitus

Indexed keywords

BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL ESTERIFICATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT RESPONSE;

ADULT; BEZAFIBRATE; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLACEBOS; SIMVASTATIN;

EID: 84871606037     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120323     Document Type: Article

References (30)

1. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010;31:149-64.
2. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
3. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10. (Pubitemid 47481452)
4. Borggreve SE, De Vries R, Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69. (Pubitemid 38019139)
5. Dallinga-Thie GM, Dullaart RPF, Van Tol A. Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: consequences for atherosclerosis development. Curr Diab Rep 2008;8:65-70. (Pubitemid 351384878)
6. de Vries R, Perton FG, Dallinga-Thie GM, et al. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005;54:3554-9. (Pubitemid 43334349)
7. Zeller M, Masson D, Farnier M, et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007;50:1948-55. (Pubitemid 350046332)
8. Kappelle PJ, Perton F, Hillege HL, Dallinga-Thie GM, Dullaart RPF. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: A nested case-control study. Atherosclerosis 2011;217:249-52.
9. Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RPF. Cholesteryl Ester Transfer Protein Inhibition in Cardiovascular Risk Management: Ongoing Trials will End the Confusion. Cardiovasc Ther 2011;29:e89-99.
10. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157:352-60.
11. Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.
12. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. (Pubitemid 350146106)
13. Neeli H, Rader DJ. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Cardiol Clin 2008;26:537-46.
14. Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJ. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995;44:460-5.
15. Guérin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to LDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189-97. (Pubitemid 30048363)
16. Guérin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progresssive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163:287-96. (Pubitemid 34615819)
17. de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RPF. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced and is unaffected by simvastatin treatment. Diabetologia 2005;48:1105-13. (Pubitemid 40909645)
18. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998;138:217-25. (Pubitemid 28255170)
19. Guérin M, Le Goff W, Frisdal E, et al. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 2003;88:3738-46. (Pubitemid 37034522)
20. Kappelle PJ, Zwang L, Huisman MV, et al. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein. Expert Opin Ther Targets 2009;13:743-51.
21. Homma Y, Ozawa H, Kobayashi T, Yamaguchi H, Sakane H, Nakamura H. Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia. Atherosclerosis 1995;114:223-34.
22. Riemens S, van Tol A, Sluiter W, Dullaart RPF. Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 1998;140:71-9. (Pubitemid 28378456)
23. Sutherland WH, Walker RJ, Lewis-Barned NJ, Pratt H, Tillman HC. Plasma cholesteryl ester transfer in patients with non-insulin dependent diabetes mellitus. Clin Chim Acta 1994;231:29-38. (Pubitemid 24372389)
24. Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res 1981;22:1206-13. (Pubitemid 12173297)
25. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000;247:563-9. (Pubitemid 30318059)
26. Muhlestein JB, May HT, Jensen JR, et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006;48:396-401.
27. The Accord study group. Effects of combination lipid therapy in type 2 diabetes mellitus. New Engl J Med 2010;362;1563-74.
28. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis 1993;104:69-77. (Pubitemid 24035634)
29. Passarelli M, Catanozi S, Nakandakare ER, et al. Plasma lipoproteins from patients with poorly controlled diabetes mellitus and "in vitro" glycation of lipoproteins enhance the transfer rate of cholesteryl ester from HDL to apo-B-containing lipoproteins. Diabetologia 1997;40:1085-93. (Pubitemid 27381972)
30. Fielding CJ, Fielding PE. Regulation of human plasma lecithin:cholesterol acyltransferase activity by lipoprotein acceptor cholesteryl ester content. J Biol Chem 1981;256:2102-4. (Pubitemid 11151463)